Does ABIRATERONE Cause Hormone-refractory prostate cancer? 83 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 83 reports of Hormone-refractory prostate cancer have been filed in association with ABIRATERONE (Abiraterone Acetate). This represents 0.2% of all adverse event reports for ABIRATERONE.
83
Reports of Hormone-refractory prostate cancer with ABIRATERONE
0.2%
of all ABIRATERONE reports
6
Deaths
5
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From ABIRATERONE?
Of the 83 reports, 6 (7.2%) resulted in death, 5 (6.0%) required hospitalization.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ABIRATERONE. However, 83 reports have been filed with the FAERS database.
What Other Side Effects Does ABIRATERONE Cause?
Death (5,623)
Fatigue (1,928)
Drug ineffective (1,732)
Therapy cessation (1,602)
Prostatic specific antigen increased (1,581)
Disease progression (1,098)
Hospitalisation (1,034)
Hot flush (989)
Asthenia (891)
Off label use (859)
What Other Drugs Cause Hormone-refractory prostate cancer?
RADIUM RA-223 DICHLORIDE (441)
LEUPROLIDE (180)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
DAROLUTAMIDE (104)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
CARBOPLATIN (27)
Which ABIRATERONE Alternatives Have Lower Hormone-refractory prostate cancer Risk?
ABIRATERONE vs ABIRATERONE\ABIRATERONE
ABIRATERONE vs ABOBOTULINUMTOXINA
ABIRATERONE vs ABRAXANE
ABIRATERONE vs ABROCITINIB
ABIRATERONE vs ACALABRUTINIB